Keryx Biopharmaceuticals (KERX)
Keryx Biopharmaceuticals Return on Equity: -98.24%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
KERX Return on Equity Rankings
| Overall | 3rd percentile | 3924 of 4055 |
| Sector | 14th percentile | 393 of 458 in Healthcare |
| Industry | 16th percentile | 20 of 24 in Drug Manufacturers - Major |
KERX Return on Equity Range, Past 5 Years
| Minimum | -622.4% | Mar 2009 |
| Maximum | 117.2% | Sep 2009 |
| Average | -114.0% |
About Return on Equity (ROE)
Click "Learn More" below to see how YCharts calculates Return on Equity.
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities). In other words, ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
You may also be interested in these KERX related companies
KERX News
$KERX and i was thinking 2, two weeks ago! I was wrong. counting on u being right
about 9 hours ago by Bleedblue
about 9 hours ago by Bleedblue
$AMRN $kerx $arna $gale bullish on all with FDA Asco such events on the way
about 9 hours ago by newkidontheblock
about 9 hours ago by newkidontheblock
Ceo has over 400k shares conditional upon positive zerenex and fda approval. Thats a big carrot! $kerx is best when volume dry and lonely...
about 9 hours ago by HighRiskBuyer
about 9 hours ago by HighRiskBuyer
RT @gregthor $KERX must have been a helluva presentation this past weekend. Get far wealthier trading other stocks thn $KERX (POS).
about 12 hours ago by JasonMilano8
about 12 hours ago by JasonMilano8
@adamfeuerstein @Gekkowire what do these free shares mean? $kerx
about 13 hours ago by GucciMoccasins
about 13 hours ago by GucciMoccasins
$KERX must have been a helluva presentation this past weekend. Get far wealthier trading other stocks thn $KERX (POS).
about 15 hours ago by gregthor
about 15 hours ago by gregthor
$KERX Stock better run soon ugh money tied up is less money to be had
about 17 hours ago by newkidontheblock
about 17 hours ago by newkidontheblock
$AMRN will buy at $10.55, $KERX will buy at $1.66, $SPPI will buy at $10.75
about 17 hours ago by JasonMilano8
about 17 hours ago by JasonMilano8
RT @traderstewie $KERX Why is this quote feed 15 minutes old? WTF is going on with quotes today? SO delayed.
about 18 hours ago by SomeGuy900
about 18 hours ago by SomeGuy900
$KERX Why is this quote feed 15 minutes old? WTF is going on with quotes today? SO delayed.
about 19 hours ago by SomeGuy900
about 19 hours ago by SomeGuy900
$KERX Reading rumors about secondary offering. Do you think it could happen? This stock is like playing craps in Vegas.
about 20 hours ago by Scott_biotech
about 20 hours ago by Scott_biotech
$kerx nevermind, i see it now. Looking for 2 today and more the next couple of days.
about a day ago by HighRiskBuyer
about a day ago by HighRiskBuyer
M&A Activity and Growing Rate of FDA Approvals Contributing Factors to Biotech Industry's Recent Boom
May 21, 8:20AM Marketwire
May 21, 8:20AM Marketwire
BMC Software, The Ultimate Software Group Included in Stocks Up on High Volume Monday
May 14, 12:33PM Fox Business
May 14, 12:33PM Fox Business
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
Unusual 11 Mid-Day Movers 05/10: (ADY) (INSP) (RPRX) Higher; (SGI) (WFR) (ARX) Lower
May 10, 2:24PM Street Insider
May 10, 2:24PM Street Insider
UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT
May 10, 10:54AM Benzinga
May 10, 10:54AM Benzinga
Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference
May 10, 8:30AM PR Newswire
May 10, 8:30AM PR Newswire
Aeterna (AEZS), Keryx (KERX) Terminate Perifosine License Agreement in North America
May 07, 7:40AM Street Insider
May 07, 7:40AM Street Insider
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KERX | 1.70 | -0.05 | -2.86% | 120.73M |
| KALU | 50.67 | +1.21 | +2.45% | 975.40M |
| K | 50.48 | +0.21 | +0.42% | 18.03B |
| JYF | 32.24 | -0.09 | -0.28% | |
| JXSB | 17.76 | +0.42 | +2.40% | 34.09M |
| JXI | 40.61 | -0.21 | -0.51% | |
| JWN | 51.08 | +0.34 | +0.67% | 10.62B |
| JVA | 7.89 | +0.30 | +3.95% | 50.26M |
| JTP | 8.26 | -0.01 | -0.12% | |
| JST | 7.25 | -0.35 | -4.61% | 118.90M |
